

Conference Intelligence Dossier: EASD Annual Meeting 2009

<https://marketpublishers.com/r/C1A1DF24886EN.html>

Date: October 2009

Pages: 90

Price: US\$ 995.00 (Single User License)

ID: C1A1DF24886EN

Abstracts

The numbers are staggering: More than 200 million people around the world now suffer from diabetes and its major complications. According to the World Health Organization, that figure is expected to surpass 366 million by 2030—even if obesity rates remain constant.i

The race to find innovative new treatments, pharmaceutical advances, and therapies is on. Recently, at the annual European Association for the Study of Diabetes (EASD) conference, the diabetes research community gathered in Vienna to discuss the latest findings.

The conference, held from September 29 to October 2, heard scientists, researchers and, key thinkers report on everything from incretin-based therapies and positive outcomes in the LEAD studies showing liraglutide usage in obese type 2 diabetes patients, to updates for a host of other GLP-1 analogues. In addition, several breakthroughs in new therapeutic agents like SGLT2 inhibitors and DPP-IV Inhibitors -considered an emerging option in hyperglycaemia management - took centre stage.

FirstWord's Conference Intelligence Dossier: EASD Annual Meeting 2009 offers you a window into the symposium attended by more than 17,000 international endocrinologists, diabetologists, scientists, and researchers. A platform for showcasing numerous research efforts and treatment discoveries, the 45th annual EASD conference expanded the knowledge base through discussions of therapeutic breakthroughs, developments, and drug profiles.

Key insights from the conference

Over 90 pages, FirstWord's conference dossier efficiently gathers the relevant information, from analyses of headlining abstracts delivered by world-renowned researchers to insightful interviews with key industry voices. The dossier provides an accurate, concise overview of all aspects of the conference, including posters, biographies, and research highlights focused on diabetes and obesity pathogenesis. In addition, FirstWord's Conference Intelligence Dossier: EASD Annual Meeting 2009 includes a unique counterpoint segment on the conference's social media activities, which outlines ways in which health care professionals and diabetes specialists might use new technology to engage in transparent, reciprocal, and relevant communication.

FirstWord's conference dossier offers:

Synopses of key abstracts, including all relevant drug posters

Wide-ranging analysis of new developments and research efforts focusing on emerging GLP-1 analogues, DPP-IV inhibitors, and SGLT2 therapy classes, grouped by field and including:

Liraglutide (Victoza) and results from the LEAD studies

Exenatide (Byetta) and outcomes from the DURATION-2 study highlighting the benefits of once-weekly use of exenatide over other therapies

Updates on regulatory delays affecting Takeda's DPP-4 inhibitor, alogliptin

Analysis of saxagliptin (Onglyza) , the new DPP-IV inhibitor from Bristol-Myers Squibb and AstraZeneca

Promising results for colesevelam, a bile acid sequestrant

A detailed overview of successes and misfires of social media use, as well as potential uses

Interviews with key voices, as well as key presenter biographies

Social media sites analysed:

Twitter

Facebook

Contents

EXECUTIVE SUMMARY

CLINICAL DATA

Glucagon-like peptide 1 (GLP-1) analogues

Liraglutide

LEAD 6 extension – switching from exenatide to liraglutide provides benefits

Two-year LEAD-2 study data

Liraglutide shows superiority to glimepiride in controlling β -cell function

Liraglutide improves prediabetes and glycaemic levels in obese patients

Exenatide

Exenatide improves β -cell response

Exenatide treatment in type 2 diabetes shows no increased relative risk of pancreatitis

Albiglutide

Albiglutide improves glycaemic control: time-course analysis

Taspoglutide

Lixisenatide

Post-meal pharmacodynamic profile of AVE0010

LY2189265

The EGO study analysis: LY2189265 is effective in overweight/obese patients with type 2 diabetes

Dipeptidyl peptidase 4 (DPP-4) inhibitors

Alogliptin

Saxagliptin

Saxagliptin plus metformin or glibenclamide significantly improves glycaemic control

Saxagliptin plus metformin provides long-term benefits in type 2 diabetes patients

Vildagliptin

Vildagliptin therapy shows no evidence of increasing pancreatitis risk

Sitagliptin

Sitagliptin shows efficacy for up to 2 years in type 2 diabetes, either alone or as add-on therapy

Sitagliptin plus metformin shows promise for glycaemic control, and reduced gastrointestinal side effects

Sitagliptin improves glucose tolerance in type 2 diabetes patients

Novel type 2 diabetes therapies

Dapagliflozin

Safety and efficacy of dapagliflozin add-on to metformin in type 2 diabetes patients

Safety and efficacy of dapagliflozin in patients poorly controlled with insulin plus metformin and/or thiazolidinediones

Colesevelam HCl

Glucose-lowering effects of colesevelam HCl

INCB13739

INCB13739 demonstrates improvements in HbA1c and low-density lipoprotein cholesterol in patients with type 2 diabetes

VI-0521

Glycaemic and weight loss effects of VI-0521

DIABETES AND CANCER

FIRSTWORD INTERVIEW WITH SELECTED KEY OPINION LEADERS

SOCIAL MEDIA ACTIVITY AT EASD 2009

Quantitative and qualitative activity analyses

Twitter: status updating

Facebook: social networking

Shared content: video, image and document services

Professional networking

Social media spotlights: activity analysis at EASD by constituency

Key opinion leaders

Pharmaceutical industry

Professional societies

Trending topics within social media at EASD

Issues: debate, interaction, conversation and comment

Events: planned, spontaneous, formal and casual

Beyond the congress centre

Blog coverage of EASD

Counterpoints: social media representations of EASD

BIOGRAPHIES OF KEY PRESENTERS

I would like to order

Product name: Conference Intelligence Dossier: EASD Annual Meeting 2009

Product link: <https://marketpublishers.com/r/C1A1DF24886EN.html>

Price: US\$ 995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C1A1DF24886EN.html>